Administration of a 41-amino-acid TREM2 peptide recapitulates this inhibitory effect by engaging C1q, thereby attenuating microglial phagocytosis and complement-mediated synaptic loss in advanced AD [54]. The gene discussed is TREM2; the disease is Alzheimer disease.